Treatment Results, Including Clinical Prognostic Factors and MGMT Gene Promoter Methylation, in Patients With Glioblastoma Multiforme in Warmia and Mazury Oncology Centre

Wspolczesna Onkologia - Poland
doi 10.5114/wo.2011.24313
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Personalized Treatment Strategies in Glioblastoma: MGMT Promoter Methylation Status

OncoTargets and Therapy
OncologyPharmacology
2013English

Prognostic Value of MGMT Promoter Methylation in Glioblastoma Patients Treated With Temozolomide-Based Chemoradiation: A Portuguese Multicentre Study

Oncology Reports
MedicineCancer ResearchOncology
2010English

The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis

PLoS ONE
Multidisciplinary
2014English

Efficacy of Clinical Prognostic Factors on Survival in Patients With Glioblastoma

Turkish Neurosurgery
SurgeryNeurology
2009English

MGMT Promoter Methylation Cutoff With Safety Margin for Selecting Glioblastoma Patients Into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.

Clinical Cancer Research
Cancer ResearchOncology
2018English

Prognostic Factors for Glioblastoma Multiforme: Development of a Prognostic Index

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1996English

Gene Expression and Promoter Methylation of Angiogenic and Lymphangiogenic Factors as Prognostic Markers in Melanoma

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Treatment Results and Prognostic Factors in 73 Patients With Nasopharyngeal Carcinoma.

Japanese jornal of Head and Neck Cancer
1997English

Prognostic or Predictive Value of MGMT Promoter Methylation in Gliomas Depends on IDH1 Mutation

Neurology
Neurology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy